Clinical Trial

Tocilizumab in Chronic Inflammatory CPPD Disease

Study acronym: TociCCAre
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aim of this clinical trial is to determine the efficacy of tocilizumab (an IL-6 inhibitor) in treatment-refractory chronic inflammatory forms of CPPD. The main questions this trial aims to answer are: * Can tocilizumab improve joint pain in patients with chronic inflammatory CPPD disease? * Does tocilizumab improve quality of life in patients with chronic inflammatory CPPD disease? Participants will receive a monthly infusion of tocilizumab or placebo for three months.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-19; most recent amendment 2026-01-13.
Trial Details
NCT Number NCT07254637
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Collaborators: Fresenius AG
Conditions Calcium Pyrophosphate Deposition Disease
Enrollment 80 participants
Start Date 2026-04
Primary Completion 2026-10 (estimated)
Study Completion 2029-11 (estimated)
Updated on ClinicalTrials.gov 2026-01-14